Street View: Pfizer’s new weight-loss drug data gets mixed appraisals
Pfizer PFE.N on Tuesday reported trial results for a key obesity drug acquired in its recent $10 billion Metsera deal, revealing data that raises concerns about how well patients may tolerate it
Median PT of 29 brokerages covering the stock is $28 - data compiled by LSEG
UP AGAINST GLP-1 DRUGS
J.P. Morgan ("neutral") says weight-loss results for the drug look competitive — slightly below Zepbound, but supported by the advantage of monthly dosing
Leerink Partners ("market perform," PT: $26) says U.S. exclusivity for PFE's cardiovascular drug Vyndaqel/Vyndamax would need to extend beyond 2028 for co to return to growth in 2029
Jefferies ("buy," PT: $34) says the drug's once-monthly efficacy looks similar to semaglutide, but says there are lingering questions about gastrointestinal side effects; says co’s long-acting GLP-1/amylin (dual-hormone obesity drugs) combo could be more promising
Morningstar (fair value: $32) says co faces key 2026–28 patent losses led by Vyndaqel and blood thinner Eliquis, and thinks oncology assets, Metsera and small-molecule programs could help it emerge as a strong obesity-market contender by the end of the decade
Related Articles
National Debt Bomb Ignited? Musk Warns U.S. Will Be 1000% Bankrupt Without AI
TradingKey - Tesla (TSLA) CEO Elon Musk recently issued another warning regarding the rapidly ballooning U.S. national debt. He stated clearly that without artificial intelligence and robotics, the United States will inevitably head toward fiscal bankruptcy.
Why Sanae Takaichi Winning Japan’s Diet Election Led to a Surge in Japanese Stock Indices？
TradingKey - Reports indicate that the ruling coalition led by Japanese Prime Minister Sanae Takaichi has secured a single-party majority in the parliamentary elections held on Sunday (February 8). Following the news, the yen weakened slightly, while the Nikkei Index surpassed 57,000 for the first t
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 market
